Q-omics provides the consensus-scored NPFFR1 profile across patient tissues and cancer cell-line models. NPFFR1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NPFFR1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NPFFR1 RNA expression shows 13,793 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, COAD, and GBM as cancer lineages where NPFFR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPFFR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPFFR1 survival associations across molecular data types. NPFFR1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPFFR1 RNA expression–survival associations across cancer types. High NPFFR1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, THCA, LUAD and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NPFFR1 RNA expression.
This table summarizes NPFFR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPFFR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPFFR1 shows lower tumor expression in LUSC and higher tumor expression in COAD, KIRC, THCA, READ and HNSC. The COAD box plot shows higher NPFFR1 RNA expression in tumor versus normal tissue (log2 FC = +0.888, t-test p < 0.001).
This table shows molecular features associated with NPFFR1 in patient tissues and cancer cell lines. In patient samples, NPFFR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPFFR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
